Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three brain tests combined in one study to spot dementia earlier

NCT ID NCT07812480

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers at Assiut University are studying whether three different tests, a blood marker called GFAP, a brain MRI scan, and a brain wave recording (EEG), can together help doctors tell normal aging, mild cognitive impairment, and dementia apart. The study enrolls 75 adults aged 50 to 85 in Egypt, split into groups with normal memory, mild memory problems, and dementia. Everyone completes memory and thinking assessments plus the three tests. No new treatment is given; the goal is to see if this combined approach improves diagnosis, including for dementias other than Alzheimer's disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the combined tests work, doctors could one day identify memory problems earlier and more accurately, including in Egyptian patients and for dementias beyond Alzheimer's disease.
What could go wrong
This is a small case-control study of 75 people, so it can only show whether the tests track with each other, not whether they improve real patient outcomes. Results from one Egyptian population may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include three groups matched for age, sex and educational level: from Outpatient clinic of the Department of Neurology and Psychiatry, Assiut University Hospitals healthy controls, patients with mild cognitive impairment (MCI), and patients with dementia of any etiology (Alzheimer's, vascular, Lewy body, frontotemporal and mixed dementia)

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Dementia diagnosed according to DSM -5\\ with a total Mini-Mental State Examination score \< 24 (or \< 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \< 79 to confirm cognitive impairment. 2. Mild cognitive impairment diagnosed according to established diagnostic criteria according to DSM -5. 3. Men or women of at least 50 years of age. 4. Reliable in individual data and willing to make themselves available for the duration of the study. 5. Clear written informed consent obtained from a first-degree relative for each patient participant, and from the control participant himself/herself. Exclusion Criteria: * age below 50 years . * other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past. * Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study * MRI contraindication (pacemaker, metallic implants, severe claustrophobia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia disorders Mild cognitive impairment (MCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.